Latest medical trials resulted in a greater reduction in convulsive-seizure frequency than placebo
We are very encouraged by the latest medical trial results from GW Pharmaceuticals of the application of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Among patients with Dravet syndrome, cannabidiol drug trials resulted in a greater reduction in convulsive-seizure frequency than placebo.
This trial also showed that cannabidiol reduced the frequency of convulsive seizures among children and young adults with the Dravet syndrome over a 14-week period but was associated with adverse events including somnolence and elevation of liver-enzyme levels.
Our charity Chair Galia Wilson commented on the announcement:
We are delighted that this important clinical study in patients with Dravet syndrome has been published in such a prestigious medical journal as it will draw increased attention to this debilitating disease. There is still a significant need for new therapeutic options to treat Dravet syndrome and we hope that the publication of this paper means that there will soon be another new medicine available for this condition.
Although still under professional medical analysis, we remain optimistic that the findings will lead to the availability of significantly improved medication for the safe treatment of Dravet syndrome through implementation of the cannibidiol compound.
Additional data is needed to determine the long-term efficacy and safety of cannabidiol for Dravet syndrome but certainly progress in investigating the compound is being made.